Literature DB >> 16563349

Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy.

Demelza J Needham1, Jing Xian Lee, Manfred W Beilharz.   

Abstract

We hypothesised that T(reg) cells preferentially expand/infiltrate inside murine mesotheliomas. Immunotherapy based on the manipulation of T(reg) cell populations should therefore be targeted to the tumour site. The AE17 murine mesothelioma model was used for this study. Both intra-tumoural T(reg) cells and those in the periphery of tumour-bearing mice were identified by flow cytometry. The effect on tumour growth of intra-tumoural depletion of T(reg) cells using the PC61 anti-CD25 mAb was then examined. We identified CD4+ T(reg) cells co-expressing both the CD25 cell surface marker and the transcription factor Foxp3 within murine mesotheliomas. These intra-tumoural T(reg) cells increase significantly as a percentage of total CD4+ T cells within the tumour as it grows. We showed that the depletion of intra-tumoural T(reg) cells with anti-CD25 mAb injected directly into the tumours can cause significantly reduced tumour growth. Localised, intra-tumoural depletion of T(reg) cells is a new, clinically relevant treatment option for established tumours.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16563349     DOI: 10.1016/j.bbrc.2006.03.018

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

Review 1.  The Role of Regulatory T Cells in Mesothelioma.

Authors:  Demelza J Ireland; Haydn T Kissick; Manfred W Beilharz
Journal:  Cancer Microenviron       Date:  2012-02-01

2.  Expression of CD4(+)CD25(high)CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its significance.

Authors:  Xi Zhu; Lin-Lin Ma; Tian Ye
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

3.  Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells.

Authors:  M E Christine Lutsiak; Yutaka Tagaya; Anthony J Adams; Jeffrey Schlom; Helen Sabzevari
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

Review 4.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Authors:  Adam J Bograd; Kei Suzuki; Eva Vertes; Christos Colovos; Eduardo A Morales; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Immunol Immunother       Date:  2011-09-13       Impact factor: 6.968

5.  The abnormal expression of CCR4 and CCR6 on Tregs in rheumatoid arthritis.

Authors:  Ning Li; Wei Wei; Feng Yin; Maogen Chen; Tian R Ma; Qiang Wu; Jie R Zhou; Song-Guo Zheng; Jie Han
Journal:  Int J Clin Exp Med       Date:  2015-09-15

6.  Depletion of Foxp3+ Regulatory T Cells Promotes Profibrogenic Milieu of Cholestasis-Induced Liver Injury.

Authors:  Yoon Seok Roh; Surim Park; Chae Woong Lim; Bumseok Kim
Journal:  Dig Dis Sci       Date:  2014-11-22       Impact factor: 3.199

Review 7.  Prognostic value of innate and adaptive immunity in colorectal cancer.

Authors:  Fabio Grizzi; Paolo Bianchi; Alberto Malesci; Luigi Laghi
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

8.  Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma.

Authors:  Andreas Bonertz; Jürgen Weitz; Dong-Ho Kim Pietsch; Nuh N Rahbari; Christoph Schlude; Yingzi Ge; Simone Juenger; Israel Vlodavsky; Khashayarsha Khazaie; Dirk Jaeger; Christoph Reissfelder; Dalibor Antolovic; Maximilian Aigner; Moritz Koch; Philipp Beckhove
Journal:  J Clin Invest       Date:  2009-10-05       Impact factor: 14.808

9.  Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects.

Authors:  Alla V Ivanova; Sergey V Ivanov; Ljudmila Prudkin; Daisuke Nonaka; Zhandong Liu; Anne Tsao; Ignacio Wistuba; Jack Roth; Harvey I Pass
Journal:  Mol Cancer       Date:  2009-10-24       Impact factor: 27.401

10.  Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact.

Authors:  G Alì; L Boldrini; M Lucchi; A Picchi; M Dell'Omodarme; M C Prati; A Mussi; V Corsi; G Fontanini
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.